← 返回前沿论文

靶向 BCMA/GPRC5D 的双特异性 CAR-T 细胞治疗复发/难治性多发性骨髓瘤:1 + 1 是否大于 2?

英文原题:Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?

PubMed 2024/07/23(内容时间) Lancet Haematol Q1 · IF 20.4(JCR 2025)

摘要

这条还没有中文摘要(正在补翻译)。 可以先展开下面的英文原文,或点最下面的「在 PubMed 查看」读原文献。

论文信息

作者
Li C、Mei H
第一作者单位
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China.China
通讯作者单位
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China. Electronic address: hmei@hust.edu.cn.China
期刊
The Lancet. Haematology2024 Oct
原文标识
PubMed 39059404 · DOI 10.1016/S2352-3026(24)00205-9